BIOMAT Database Logo BIOMAT Database Logo

5-Fluorouracil (NSC-19893) compared to cyclophosphamide (NSC-26271) in bronchogenic carcinoma: results of a clinical study. 1975

A Brugarolas, and A Rivas, and A J Lacave, and F Gonzalez-Palacois, and A Froufe

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002283 Carcinoma, Bronchogenic Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA. Carcinoma, Bronchial,Bronchial Carcinoma,Bronchial Carcinomas,Bronchogenic Carcinoma,Bronchogenic Carcinomas,Carcinomas, Bronchial,Carcinomas, Bronchogenic
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

A Brugarolas, and A Rivas, and A J Lacave, and F Gonzalez-Palacois, and A Froufe
Preliminary trials with combination therapy of cyclophosphamide (NSC-26271), vincristine (NSC-67574), and 5-fluorouracil (NSC-19893).
September 1968, Cancer chemotherapy reports,
A Brugarolas, and A Rivas, and A J Lacave, and F Gonzalez-Palacois, and A Froufe
Adriamycin (NSC-123127) versus 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in the treatment of metastatic prostate cancer.
January 1976, Cancer treatment reports,
A Brugarolas, and A Rivas, and A J Lacave, and F Gonzalez-Palacois, and A Froufe
[Altered sensitivity of hematopoietic stem cells to 5-fluorouracil (NSC-19893) following endotoxin (NSC-189681), cyclophosphamide (NSC-26271), or irradiation].
January 1974, Cancer chemotherapy reports,
A Brugarolas, and A Rivas, and A J Lacave, and F Gonzalez-Palacois, and A Froufe
Bleomycin (NSC-125066) followed by cyclophosphamide (NSC-26271), vincristine (NSC-67574), methotrexate (NSC-740), and 5-fllorouracil (NSC-19893) for non-oat cell bronchogenic carcinoma.
January 1976, Cancer treatment reports,
A Brugarolas, and A Rivas, and A J Lacave, and F Gonzalez-Palacois, and A Froufe
Radiation plus 5-fluorouracil (NSC-19893): clinical demonstration of an additive effect in bronchogenic carcinoma.
June 1971, Cancer chemotherapy reports,
A Brugarolas, and A Rivas, and A J Lacave, and F Gonzalez-Palacois, and A Froufe
Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer: a randomized trial.
December 1978, Cancer,
A Brugarolas, and A Rivas, and A J Lacave, and F Gonzalez-Palacois, and A Froufe
Comparison of adriamycin (NSC-123127) and the combination of 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in advanced prostatic cancer: a preliminary report.
January 1975, Cancer chemotherapy reports,
A Brugarolas, and A Rivas, and A J Lacave, and F Gonzalez-Palacois, and A Froufe
Treatment of adenocarcinoma with combinations of cyclopjosphamide (NSC-26271), vincristine (NSC-67574), and 5-fluorouracil (NSC-19893).
January 1975, Cancer chemotherapy reports,
A Brugarolas, and A Rivas, and A J Lacave, and F Gonzalez-Palacois, and A Froufe
Combination chemotherapy of bronchogenic carcinoma with cyclophosphamide (NSC-26271) and BCNU (NSC-409962).
January 1974, Cancer chemotherapy reports,
A Brugarolas, and A Rivas, and A J Lacave, and F Gonzalez-Palacois, and A Froufe
Cyclophosphamide (NSC-26271) as adjuvant to radiotherapy in the treatment of unresectable bronchogenic carcinoma.
March 1973, Cancer chemotherapy reports. Part 3,
Copied contents to your clipboard!